
|Videos|September 10, 2014
A Phase Ib Study of Abiraterone Plus Docetaxel for mCRPC
Author(s)Edwin M. Posadas, MD, FACP
Edwin M. Posadas, MD, FACP, discusses the results of a phase Ib study that looked at abiraterone and docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Advertisement
Clinical Pearls
Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses the results of a phase Ib study that looked at abiraterone and docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
- Some oncologists are unsure about whether abiraterone or docetaxel is more appropriate for patients with mCRPC. Combining the agents could maximize outcomes for patients.
- This phase Ib showed that the combination was well tolerated.
More about this study > >
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
2
Cost-Effectiveness of Perioperative Pembro in Head and Neck Cancer Hinges on PD-L1 Expression
3
FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs
4
Dr Lonial on Using MRD Negativity to Guide Maintenance Discontinuation in Myeloma
5







































